Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 3, 2026

AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth

View original at globenewswire.com
AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "AI in Genomics Market, till 2040: Distribution by Type of Component, Type of Technology, Type of Functionality…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The rapid increase in genomic data generated by next-generation sequencing technologies has created a strong demand for AI-based tools capable of managing and analyzing complex datasets

    80% confidence
  • The AI in genomics market will grow at a CAGR of 43.75% during the forecast period till 2040

    80% confidence
  • Machine learning algorithms are enabling faster identification of genetic patterns, disease prediction, and drug target discovery, thereby significantly reducing both cost and time in research and development

    80% confidence
  • The global AI in genomics market size is estimated to grow from USD 1.97 billion in 2026 to USD 317.4 billion by 2040

    80% confidence
  • Drug development has traditionally been a lengthy and costly process, often taking several years and substantial investment, but AI-driven tools now enable rapid analysis of vast biomedical datasets

    80% confidence
  • The AI in genomics market faces several critical challenges including data quality and standardization issues, data privacy and compliance concerns, high computational costs, limited availability of skilled AI professionals, and lack of model interpretability

    80% confidence
  • AI algorithms can predict molecular interactions, optimize lead compounds, and identify potential drug candidates with higher precision

    80% confidence
  • The integration of AI into drug discovery and genomics is reshaping the healthcare landscape, expediting innovation, and advancing the global shift toward precision medicine

    80% confidence
  • The market for AI in genomics is expected to grow significantly due to the massive increase in genomic data from next-generation sequencing technologies, which outpaces traditional analysis methods and requires AI's pattern recognition capabilities

    80% confidence
  • Artificial intelligence is transforming the field of genomics by processing huge datasets from DNA sequencing to reveal insights that conventional techniques overlook

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com